Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastom... by Raub, Thomas J, Wishart, Graham N, Kulanthaivel, Palaniappan, Staton, Brian A, Ajamie, Rose T, Sawada, Geri A, Gelbert, Lawrence M, Shannon, Harlan E, Sanchez-Martinez, Concepcion, De Dios, Alfonso

Get full text

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenograft... by TATE, Sonya C, SHUFEN CAI, AJAMIE, Rose T, BURKE, Teresa, BECKMANN, Richard P, CHAN, Edward M, DE DIOS, Alfonso, WISHART, Graham N, GELBERT, Lawrence M, CRONIER, Damien M

Get full text

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine by Gelbert, Lawrence M., Cai, Shufen, Lin, Xi, Sanchez-Martinez, Concepcion, del Prado, Miriam, Lallena, Maria Jose, Torres, Raquel, Ajamie, Rose T., Wishart, Graham N., Flack, Robert Steven, Neubauer, Blake Lee, Young, Jamie, Chan, Edward M., Iversen, Philip, Cronier, Damien, Kreklau, Emiko, de Dios, Alfonso

Get full text

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models by Yin, Tinggui, Lallena, Maria J, Kreklau, Emiko L, Fales, Kevin R, Carballares, Santiago, Torrres, Raquel, Wishart, Graham N, Ajamie, Rose T, Cronier, Damien M, Iversen, Phillip W, Meier, Timothy I, Foreman, Robert T, Zeckner, Douglas, Sissons, Sean E, Halstead, Bart W, Lin, Aimee B, Donoho, Gregory P, Qian, Yuewei, Li, Shuyu, Wu, Song, Aggarwal, Amit, Ye, Xiang S, Starling, James J, Gaynor, Richard B, de Dios, Alfonso, Du, Jian

Get full text

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth by Smith, Michele C, Mader, Mary M, Cook, James A, Iversen, Philip, Ajamie, Rose, Perkins, Everett, Bloem, Laura, Yip, Yvonne Y, Barda, David A, Waid, Philip P, Zeckner, Douglas J, Young, Debra A, Sanchez-Felix, Manuel, Donoho, Gregory P, Wacheck, Volker

Get full text

Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs by Lucas, Andrew T., Herity, Leah B., Kornblum, Zack A., Madden, Andrew J., Gabizon, Alberto, Kabanov, Alexander V., Ajamie, Rose T., Bender, David M., Kulanthaivel, Palaniappan, Sanchez-Felix, Manuel V., Havel, Henry A., Zamboni, William C.

Get full text

Validation of 96-well Equilibrium Dialysis with Non-radiolabeled Drug for Definitive Measurement of Protein Binding and Application to Clinical Development of Highly-Bound Drugs by Zamek-Gliszczynski, Maciej J., Ruterbories, Kenneth J., Ajamie, Rose T., Wickremsinhe, Enaksha R., Pothuri, Lavanya, Rao, Mukkavilli V.S., Basavanakatti, Vinay N., Pinjari, Jakir, Ramanathan, Vikram K., Chaudhary, Ajai K.

Get full text

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft mo... by Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.

Get full text

Tetrahydroisoquinoline PPARγ agonists: Design of novel, highly selective non-TZD antihyperglycemic agents by Henry, James R., Li, Yihong, Warshawsky, Alan M., Brozinick, Joseph T., Hawkins, Eric D., Misener, Elizabeth A., Briere, Daniel A., Montrose-Rafizadeh, Chahrzad, Zink, Richard W., Yumibe, Nathan P., Ajamie, Rose T., Wilken, Brad, Devanarayan, Viswanath

Get full text

Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against in... by Sanchez-Martinez, Concepcion, Gelbert, Lawrence M., Shannon, Harlan, De Dios, Alfonso, Staton, Brian A., Ajamie, Rose T., Sawada, Geri, Wishart, Graham N., Raub, Thomas J.

Get full text

Abstract 352: Preclinical evaluation of LYS6K1, a novel, highly selective, orally bioavailable inhibitor of p70 S6 kinase currently in phase I clinical trials for cancer by Geeganage, Sandaruwan, Sams, Lillian L., Joseph, Sajan, Brail, Leslie, Wang, Tao, Rodgers, George, Akunda, Jackie, Huang, Jianping, Perkins, Everett J., Ajamie, Rose

Get full text

Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity by Gelbert, Lawrence M., Cai, Shufen, Lin, Xi, Sanchez-Martinez, Concepcion, del Prado, Miriam, Lallena, Maria Jose, Torres, Raquel, Ajamie, Rose T., Kreklau, Emiko, Wishart, Graham N., Flack, Robert Steven, Neubauer, Blake, Young, Jamie, Chan, Edward M., Iversen, Phillip, Cronier, Damien, De Dios, Alfonso

Get full text

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents by Henry, James R, Li, Yihong, Warshawsky, Alan M, Brozinick, Joseph T, Hawkins, Eric D, Misener, Elizabeth A, Briere, Daniel A, Montrose-Rafizadeh, Chahrzad, Zink, Richard W, Yumibe, Nathan P, Ajamie, Rose T, Wilken, Brad, Devanarayan, Viswanath

Get full text

Tetrahydroisoquinoline PPARrγ agonists : Design of novel, highly selective non-TZD antihyperglycemic agents by HENRY, James R, YIHONG LI, AJAMIE, Rose T, WILKEN, Brad, DEVANARAYAN, Viswanath, WARSHAWSKY, Alan M, BROZINICK, Joseph T, HAWKINS, Eric D, MISENER, Elizabeth A, BRIERE, Daniel A, MONTROSE-RAFIZADEH, Chahrzad, ZINK, Richard W, YUMIBE, Nathan P

Get full text